Combination therapy with bi-3406 and venetoclax improves outcomes in tumors with oncogenic kras variants, indicating potential for broader cancer treatment strategies.
Figure S16. Combination activity of BI-3406 with venetoclax in multicell-type tumor spheroids.
No takes yet. Share an insight, caveat, or question.
Davoudi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: